Aurobindo Pharma Ltd Research Report - 23rd Feb 2017

Pharmaceutical | Published on Feb 23rd 2017


For 3QFY2017, Aurobindo Pharma (APL) posted numbers which were almost inline with expectations on sales and net profit front, with sales marginally higher than expected and net profit marginally lower than expected. On sales front, the company posted sales of Rs3844cr (v/s. Rs3,715cr expected) v/s. Rs3,432cr in 3QFY2016, posting a yoy growth of 12.0%. On the operating front, the EBITDA margin came in at 21.7% (vs. 23.1% expected) v/s. 22.1% in 3QFY2016. Consequently, the Adj. PAT came in at Rs579cr (v/s. Rs603cr expected) v/s. Rs544cr in 3QFY2016, a yoy growth of 6.3%. We maintain our Buy rating on the stock.

Download Full Report


CMP 686
Target Price 877
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Public & Others11.0
Grand Total100.0

Trade Securely


Portfolio Tracking & Trading Application View Demo